Characteristic | N (%) |
---|---|
The median age, range (yrs) | 56, 30–83 |
Gender | |
 Male | 53 (43.1) |
 Female | 70 (56.9) |
Primary tumor | |
 NSCLC | 73 (59.3) |
 SCLC | 20 (16.3) |
 BC | 22 (17.9) |
 Others | 8 (6.5) |
Gene mutation | |
 EGFR | 47 (38.2) |
 ALK | 8 (6.5) |
 Her-2 | 11 (8.9) |
 BRCA | 1 (0.8) |
 None of above listed | 56 (45.5) |
BM location | |
 Cerebrum | 93 (75.6) |
 Cerebellum | 29 (23.6) |
 Brainstem | 1 (0.8) |
KPS | |
  ≥ 80 | 94 (76.4) |
  < 80 | 29 (23.6) |
BM volume | |
  ≥ 6 cc | 72 (58.5) |
  < 6 cc | 51 (41.5) |
RT regimens | |
 PCI or previous WBRT | 33 (26.8) |
 HFRT alone | 69 (56.1) |
 SRS concurrent with WBRT | 21 (17.1) |
Systemic treatments | |
 Chemotherapy | 57 (46.3) |
 TMZ | 56 (45.5) |
 Targeted therapy | 61 (49.6) |
 Immunotherapy | 7 (5.7) |